TRAWS PHARMA REPORTS FINAL PHASE 2A RESULTS FOR RATUTRELVIR IN COVID-INFECTED SUBJECTS, SHOWING FEWER TREATMENT-RELATED ADVERSE EVENTS AND NO VIRAL REBOUNDS VERSUS PAXLOVID®

Reuters · 2d ago

Please log in to view news